Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ritonavir

FDA-approved product (solution, oral), marketed as Norvir, Ritonavir.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ritonavir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Hepatitis C virus infection
  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
FDA pharmacologic class
Cytochrome P450 3A Inhibitor; Protease Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ritonavir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ritonavir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

    NCT03727152 · start 2019-05-01

    Registered record
    Registry ID
    NCT03727152
    Conditions
    HIV
    Interventions
    generic single tablet TAF/FTC/DTG
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-05-01
    Completion
    2023-04-04
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiongeneric single tablet TAF/FTC/DTG
    PhasePhase 3
    Registry statusCompleted

  • Effect Of DAAs For Treatment Of HCV On Normal Kidney

    NCT03296930 · start 2017-10-01

    Registered record
    Registry ID
    NCT03296930
    Conditions
    Antiviral Drug Adverse Reaction
    Interventions
    Sofosbuvir 400 MG Oral Tablet,; Ombitasvir/paritaprevir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-10-01
    Completion
    2018-10-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiviral Drug Adverse Reaction
    InterventionSofosbuvir 400 MG Oral Tablet,; Ombitasvir/paritaprevir/ritonavir
    PhasePhase 4
    Registry statusUnknown

  • Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C

    NCT02725866 · start 2016-04-05

    Registered record
    Registry ID
    NCT02725866
    Conditions
    Chronic Hepatitis C
    Interventions
    Paritaprevir/ritonavir/ombitasvir; Dasabuvir; Ribavirin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2016-04-05
    Completion
    2017-10-31
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionParitaprevir/ritonavir/ombitasvir; Dasabuvir; Ribavirin
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

    NCT02652624 · start 2016-02-19

    Registered record
    Registry ID
    NCT02652624
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; E/C/F/TDF; ATV; RTV; FTC/TDF; B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-19
    Completion
    2018-11-26
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; E/C/F/TDF; ATV; RTV +2 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics

    NCT02531321 · start 2015-08

    Registered record
    Registry ID
    NCT02531321
    Conditions
    Contraception; HIV
    Interventions
    Levonorgestrel and Ethinyl Estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-08
    Completion
    2016-11-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception; HIV
    InterventionLevonorgestrel and Ethinyl Estradiol
    PhasePhase 4
    Registry statusTerminated

  • HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

    NCT02513147 · start 2015-06

    Registered record
    Registry ID
    NCT02513147
    Conditions
    HIV-1
    Interventions
    Dolutegravir; PI; 2 NRTI; 2 NRTI
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-06
    Completion
    2016-11
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1
    InterventionDolutegravir; PI; 2 NRTI; 2 NRTI
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection

    NCT02068222 · start 2014-04

    Registered record
    Registry ID
    NCT02068222
    Conditions
    Chronic Hepatitis C; Hepatitis C Virus
    Interventions
    ABT-450/ritonavir (r); ABT-530; Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-03
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Hepatitis C Virus
    InterventionABT-450/ritonavir (r); ABT-530; Ribavirin (RBV)
    PhasePhase 2
    Registry statusCompleted

  • A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants

    NCT02064842 · start 2014-02

    Registered record
    Registry ID
    NCT02064842
    Conditions
    Healthy
    Interventions
    TMC647055; TMC435; Placebo; Ritonavir (RTV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-02
    Completion
    2014-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTMC647055; TMC435; Placebo; Ritonavir (RTV)
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers

    NCT03832426 · start 2013-11-08

    Registered record
    Registry ID
    NCT03832426
    Conditions
    Hepatic Impairment
    Interventions
    Narlaprevir; Ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11-08
    Completion
    2014-10-24
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionNarlaprevir; Ritonavir
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection

    NCT01767116 · start 2012-12

    Registered record
    Registry ID
    NCT01767116
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    ABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-08
    Enrolment
    419

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ribavirin
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Chronic Hepatitis C Infection

    NCT01716585 · start 2012-11

    Registered record
    Registry ID
    NCT01716585
    Conditions
    Chronic Hepatitis C Infection
    Interventions
    ABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ABT-450/r/ABT-267; Placebo for ABT-333; Placebo for ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-10
    Enrolment
    636

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C Infection
    InterventionABT-450/r/ABT-267, ABT-333; Ribavirin; Placebo for ABT-450/r/ABT-267; Placebo for ABT-333 +1 more
    PhasePhase 3
    Registry statusCompleted

  • DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

    NCT01423812 · start 2012-01

    Registered record
    Registry ID
    NCT01423812
    Conditions
    HIV
    Interventions
    Twice-daily combination Darunavir and ritonavir; Once-daily combination Darunavir and ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2015-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTwice-daily combination Darunavir and ritonavir; Once-daily combination Darunavir and ritonavir
    PhasePhase 4
    Registry statusCompleted

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated